Takeda Pharmaceutical Co Ltd
TAK
Company Profile
Business description
Takeda Pharmaceutical is Japan’s largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company’s five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.
Contact
1-1, Nihonbashi-Honcho 2-Chome
Chuo-ku
Tokyo103-8668
JPNT: +81 332782306
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2026
Employees
47,455
Stocks News & Analysis
stocks
Chart of the Week: Inflation fears dampen sentiment on retailers
Rising inflation is the fly in the ointment.
stocks
Here’s 3 Top Rated ASX shares for 2026
As we start the new year, let’s take a closer look at three compelling opportunities on the ASX
stocks
Undervalued Aussie e-commerce winner
Shares attractive due to near term profit margin increase and structural growth.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,046.50 | 7.00 | 0.08% |
| CAC 40 | 8,209.78 | 27.65 | -0.34% |
| DAX 40 | 25,063.04 | 59.22 | -0.24% |
| Dow JONES (US) | 48,996.08 | 466.00 | -0.94% |
| FTSE 100 | 10,019.43 | 28.78 | -0.29% |
| HKSE | 26,149.31 | 561.14 | -2.10% |
| NASDAQ | 23,584.28 | 37.10 | 0.16% |
| Nikkei 225 | 51,117.26 | 1,400.82 | -2.67% |
| NZX 50 Index | 13,716.86 | 1.84 | 0.01% |
| S&P 500 | 6,920.93 | 23.89 | -0.34% |
| S&P/ASX 200 | 8,720.80 | 2.70 | -0.03% |
| SSE Composite Index | 4,082.98 | 2.79 | -0.07% |